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Abstract 
Cancer is associated with an increased risk of venous thromboembolism (VTE); the exact 
mechanisms for the induction of VTE remain to be fully elucidated, yet it is widely 
acknowledged that tissue factor-positive microparticles (TF-MPs) may play a significant role. 
However, TF-MPs have yet to be accepted as a bona fide biomarker for cancer-associated VTE, 
as the presence of elevated TF-MPs levels is not always accompanied by thrombosis; 
interestingly in certain cases, particularly in pancreatic cancer, VTE seems to be more likely in 
the context of acute inflammation. While several potential mechanisms for the development 
of VTE in cancer have been postulated, this review explores the homeostatic disruption of TF-
MPs, as the main reservoir of blood-borne TF, in the context of cancer and inflammation, and 
considers the abrogated responses of the activated endothelium and mononuclear phagocyte 
system in mediating this disruption.  
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DVT formation in vivo 
The exact mechanisms that induce clotting in venous thromboembolism (VTE) have yet to be 
fully elucidated. Although arterial thrombosis is shown to be provoked by endothelial 
disruption, a frequent model described for deep vein thrombosis (DVT) is venous stasis in the 
absence of endothelial injury (except in thrombosis associated with surgery) [1, 2]. The most 
common site for DVT initiation in humans is the valve pocket sinuses of the calf veins due to 
periods of blood stasis and low oxygen levels, and therefore a predisposition to become 
hypoxic [3]. The endothelium is activated by hypoxia and/or inflammatory stimuli, leading to 
the expression of adhesion receptors platelet selectin (P-selectin), endothelial selectin (E-
selectin) and von Willebrand factor (vWF) on the endothelium that facilitate the binding of 
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circulating leukocytes (specifically neutrophils and monocytes), platelets and microparticles 
(MPs) [4-6]. In contrast, the normal endothelium prevents thrombosis by inhibiting the 
attachment of cells and proteins necessary for clotting, expressing anticoagulants (including 
tissue factor pathway inhibitor [TFPI], thrombomodulin (TM), endothelial protein C receptor, 
and heparin-like proteoglycans), and releasing platelet inhibitors (nitric oxide and prostacyclin) 
[7, 8]. However, following endothelial cell (EC) activation, TM is downregulated, while 
expression of tissue factor (TF), the primary initiator of the extrinsic coagulation cascade, is 
increased on the cell surface [9], shifting the haemostatic balance towards a hypercoagulable 
state. In addition, the endothelial-bound leukocytes become activated and express TF, 
initiating the activation of the coagulation cascade, and inducing thrombosis [10, 11]. 
This proposed sequence of events is supported by a recent novel study employing a mouse 
inferior vena cava (IVC) stenosis model for DVT initiation and propagation [11], identifying 
neutrophils as the predominant leukocytes recruited to the activated endothelium and present 
during the early stages of thrombosis. The study found that in mice expressing minimal levels 
of TF on myeloid leukocyte cells, the development of venous thrombosis was considerably 
reduced, implying that leukocyte-derived TF plays a key role in the initiation of thrombus 
formation in this model. Additionally, von Bruhl et al. confirm that platelets contribute to DVT 
propagation by binding to leukocytes and promoting secondary leukocyte recruitment at the 
thrombus site and, in agreement with others, suggested that neutrophils amplify DVT 
development by forming neutrophil extracellular DNA traps (NETs), which trigger Factor XII 
(FXII)-dependent coagulation via the contact pathway [11], and induce activation and 
aggregation of platelets via their constituent histones [12]. Indeed the specific depletion of 
neutrophils in a murine DVT model, and the degradation of NET scaffolds following treatment 
with DNase I or heparin, both resulted in a marked inhibition of thrombus formation [11, 12]. 
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VTE in cancer 
The prevalence of VTE in cancer is around four- to five-fold higher than in the general 
population [13]. This generally confers a poor prognosis and constitutes the second leading 
cause of death in cancer patients [14]. The pathogenesis of VTE in cancer patients is most likely 
a result of the interactions between cancer cells and host factors, which may be framed in the 
context of “Virchow’s triad” [15] consisting of 3 elements: venous stasis, endothelial 
injury/abnormality and hypercoagulability, which can all simultaneously account for the 
prothrombotic state in the same cancer patient. Venous stasis has been suggested to 
contribute to venous thrombosis in cancer that may manifest from immobility during a post-
operative period or debility in advanced malignancy, extrinsic compression of blood by the 
primary tumour, or tumour invasion. Furthermore, slow venous blood flow can lead to the 
improper clearance of activated clotting factors causing hyperviscosity and increasing 
incorporation of MPs into endothelial membranes resulting in the concentration of these 
factors at the endothelial surface. Accumulated clotting factors in stagnant blood could 
overwhelm local anticoagulant pathways, thus inducing a hypercoagulable state of malignancy 
that may trigger thrombosis. Endothelial injury may promote thrombosis in cancer patients as 
a result of mechanical trauma arising from tumour invasion or therapeutic interventions such 
as surgery or placement of venous catheters for chemotherapy administration, while 
endothelial dysfunction can also result from antiangiogenic stimuli and the ‘unselective’ effects 
of some chemotherapeutic agents that are toxic to ECs. All proposed mechanisms relating to 
the pathogenesis of VTE can be traced back to abnormalities in at least one of these triad 
components. 
A multitude of clinical and biological risk factors for the development of VTE in cancer patients 
have been identified and have been extensively reviewed [16, 17]. In addition to general VTE 
risk factors, cancer-driven events found to specifically promote a hypercoagulable state 
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include the increased activation of procoagulant factors with concomitant inhibition of 
anticoagulant mechanisms, impaired fibrinolysis, production and secretion of procoagulant 
substances and proinflammatory cytokines, increased platelet aggregation and adhesive 
interactions among tumour cells, endothelium and blood cells [15]. Oncogene and tumour 
suppressor gene-mediated neoplastic transformation events (e.g. activation of Met, loss of 
PTEN, induction of K-ras, loss of p53) [17] can also promote haemostatic derangement, as can 
inherited prothrombotic variants (e.g. factor V Leiden and prothrombin G20210) or 
deficiencies in antithrombin, protein C or protein S [2, 16]. Anti-cancer treatments, such as 
chemotherapy, hormonal therapy, anti-angiogenic therapy, erythropoiesis stimulating agents, 
blood transfusions and central venous lines have also been found to contribute to an increased 
risk.  
VTE risk is found to vary depending on the primary cancer site and stage of disease. While the 
highest rates are reported in pancreatic (5.3% to 26.0%) and brain (1.6% to 26.0%) cancers, 
breast (0.4% to 8.1%) and prostate (0.5% to 1.4%) cancers are found to have the lowest rates 
[16]. Rates among patients with advanced metastatic cancers are higher than in those with 
localised tumours, and histological grading also seems to be an important factor; analysis of 
data from the Vienna CATS study found the risk of developing VTE to be twice as high in 
patients with high-grade tumours (G3 and G4) compared to those with lower grade tumours 
(G1 and G2) [18]. 
A number of discriminatory parameters (e.g. tumour entity, BMI, haemoglobin level, leukocyte 
count) and putative biomarkers (e.g. D-dimer, prothrombin fragment 1+2, soluble P-selectin, 
TAT complexes, TF-bearing MPs) for VTE risk have been proposed, and several have been 
incorporated into risk assessment scores, designed to aid in identification of those cancer 
patients at high risk of thrombosis, with the aim of delivering more targeted 
thromboprophylaxis. However a recent evaluation of current risk scores in a multinational 
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prospective cohort study of patients with advanced solid cancers highlighted their poor 
discriminatory capacity, particularly when studying individual tumour types [19]. This 
emphasises the need to investigate further putative mechanisms, which can be used to 
develop more refined, and possibly even cancer-type specific models for risk prediction. 
The differences observed between cancer types suggest that identified causes of VTE may in 
fact have varying levels of influence, dependent on the cancer entity, and that VTE may even 
be triggered by distinct cancer type-specific mechanisms. In a number of cancers, and 
especially in pancreatic cancer, one of the most highly characterised mechanisms is the 
increased activation of the TF coagulation pathway, via the upregulation of TF on the surface 
of tumour cells, and subsequent release of TF-bearing MPs (TF-MPs). In contrast, in malignant 
gliomas, another highly prothrombotic malignancy type, Riedl et al. [20] suggest that the 
coagulation activation observed may be less reliant on TF, and may instead be attributed at 
least in part to high intratumoural podoplanin expression, which induces platelet activation 
and aggregation, and was found to correlate with hypercoagulability. In prostate cancer, which 
has a comparatively much lower associated risk of VTE, the polyphosphate-factor XII pathway 
is postulated as a main driver of thrombosis [21]. 
 
The contribution of TF to cancer-associated thrombosis 
TF expression can be induced in a variety of cell types, and recent evidence from in vivo studies 
suggests that not only arterial, but also venous thrombosis is initiated by intravascular TF, 
involving multicellular interactions at the site of ongoing thrombosis [11, 22]. Cancer-
associated thrombosis is frequently attributed to high levels of TF expression, involving 
primarily the upregulation of TF on the surface of tumour cells and their migration into the 
vascular lumen during vascular invasion and metastasis, but also TF-positive inflammatory and 
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stromal cells within the tumour microenvironment, upregulated tumour vasculature TF 
expression by angiogenic or activated ECs, and the release of TF-MPs into the blood circulation 
[23-28]. 
Patients with pancreatic cancer are at a particularly high risk of developing VTE when 
compared to other cancer types [29]. Pancreatic cancer cells often exhibit markedly high levels 
of TF expression [30-32], which have been explicitly linked to procoagulant activity in vitro [33], 
while elevated TF expression in pancreatic cancer patients has been positively correlated with 
the rate of symptomatic VTE [32]. In addition, elevated levels of tumour-derived TF-MP can be 
detected in the circulation of mice bearing human pancreatic and lung cancer cell lines and 
tumours [34-36] and it is these procoagulant MPs, rather than the parental tumour cells, that 
are found within sites of ongoing thrombosis in vivo [34, 37, 38], and have been shown to 
accumulate at sites of injury in a P-selectin-dependent manner where they aggregate platelets  
and accelerate thrombus growth [34]. The critical role of TF is emphasized by a significantly 
reduced incidence of thrombus formation in mice perfused with low-TF Panc02-derived MP 
compared with unmodified Panc02-derived MP in a murine IVC stenosis-pancreatic cancer 
model [38].  
A definitive link between TF-MPs and the development of clinical VTE has yet to be established 
and remains somewhat debated in view of conflicting evidence, as summarised in a recent 
review [39]. Differences in association could be due to varying levels of TF encryption and 
participation of TF in non-coagulant activities, such as signalling of the TF-factor VIIa (FVIIa) 
complex via protease-activated receptor 2 (PAR2) [28]. In pancreatic cancer, increased levels of 
both TF-MPs and MP-TF activity have been significantly associated with VTE [40-42] and, 
furthermore, radical pancreatectomy in pancreatic cancer patients results in a significant 
decrease in TF-MP levels [41], which is accompanied by a significant reduction in PCA [43]. The 
exact contribution of TF-MPs to the development of VTE may therefore be highly variable 
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between tumour types, and the association in pancreatic cancer may reflect the high level TF 
expression relative to other cancer types and/or the late stage of disease presentation [16]. 
Somewhat surprisingly however, while around 80% pancreatic cancer patients show increased 
TF levels, fewer than 30% of these patients are found to develop thrombosis [44], indicating 
that elevated TF-MP levels in isolation do not unequivocally trigger thrombosis, and raising the 
interesting question of why the clinically recorded thrombosis rate is so much lower. 
Intriguingly, the occurrence of a thromboembolic event in these patients is often accompanied 
by the presence of persistent inflammation. 
 
Putative role of inflammation in promoting DVT 
While TF-MP likely participate in thrombus propagation in pancreatic cancer, it is unlikely they 
represent the sole causative mechanism; indeed several other factors are proposed to 
promote a hypercoagulable state in this context [45]. It is therefore more likely that TF-MPs 
constitute an important contributory factor among other integral components within a 
multifactorial process. 
Inflammation is almost invariably accompanied by alterations to the coagulation system, and 
therefore may have a further compounding effect in the context of malignancy, an already 
hypercoagulable state, which could thereby precipitate thrombosis. Furthermore, once 
activated, coagulation pathways can markedly affect inflammatory activities, establishing a 
cycle of sequential aggravation to further amplify the host response and potentially increase 
the risk of VTE.  
Inflammation induces coagulation 
The presence of inflammation in cancer is characterized by changes in cell numbers in 
peripheral blood and levels of inflammatory cytokines. The findings of a study by von Bruhl et 
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al. suggest that massive leukocyte accumulation precedes the development of DVT in response 
to perturbed venous blood flow [11]. Pabinger and Posch [46] analysed the Vienna CATS study 
dataset to show an increase of 1 x 109/L in WBC to be associated with a 7% increase in risk of 
VTE, while the Tromsø study interestingly noted that an elevated WBC count measured even 
prior to the development of cancer was also associated with a future risk of VTE [47], hinting 
that leukocytes are not simply a reflection of low-grade inflammation, but more likely have a 
potential causal role. 
A key effect of inflammatory mediators is to induce the expression of TF on the surface of 
circulating monocytes, tissue macrophages and neutrophils, increasing the pool of TF 
potentially available to participate in coagulation. Upregulation of TF expression has been 
specifically demonstrated in vitro on human peripheral blood monocytes in response to 
proinflammatory stimuli [48-50], while TF production by neutrophils attached to an injured 
endothelium is recognized as an initiatory event in thrombus formation in DVT models [22]. 
Moreover, circulating mononuclear cells harvested from V2 carcinoma-bearing rabbits were 
found to generate significantly more PCA than those from control tumour-free animals [51]. 
On exposure to inflammatory cytokines, leukocytes are also more prone to microvesiculation 
[52] and hence thereafter capable of producing TF-MPs, which may be recruited to growing 
thrombi via P-selectin glycoprotein ligand 1 (PSGL1)-P-selectin interactions [53], and may serve 
to stabilize the thrombus by inducing fibrin formation [54]. Neutrophils can also recruit TF-MPs 
[55], while the NETs they expel have been shown in vitro to serve as a site of adherence for 
tumour-derived TF-MPs [38]. This could be an important process for localizing TF-MPs and 
concentrating additional TF into the vicinity of the developing clot. 
There is also evidence to suggest that MPs are able to transfer their procoagulant potential to 
other cell types [54] and in doing so can exacerbate endothelial activation. While TF expression 
is seen to be induced in cultured ECs in response to inflammatory mediators such as TNFα and 
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LPS endotoxin [56, 57], in vivo however it seems more likely that the TF associated with ECs is 
derived from TF-MPs released by monocytes or tumour cells [58-60]. It has been demonstrated 
that TF-MPs can arise from lipid raft regions in monocyte cell membranes and fuse with 
activated platelets enabling transfer and subsequent expression of their membrane protein 
complement (including TF), which can serve to initiate coagulation [61]; it is possible these 
MPs may interact with ECs in a similar manner. Others have suggested that exposure of 
acquired TF on the endothelial surface may occur via an endocytic recycling process [62], 
through which surplus circulating TF-MPs from cancer patients can cause upregulation of 
endothelial-expressed TF through activation of the PAR2 pathway [63], enhancing the 
coagulopathic effect. Many of the inflammatory processes that accompany the thrombosis 
process in cancer have the propensity to activate this pathway. At particularly high levels of TF, 
such as those expressed by tumour cells and induced by high levels of proinflammatory 
factors, this PAR-2 driven mechanism may become saturated. This may result in accumulation 
of TF in ECs which compromises their ability to release TF in the form of endothelial TF-MPs, 
and instead serves to promote pro-apoptotic mechanisms within ECs via upregulation of Bax 
[64], leading to endothelial denudation [65] and exposure of the sub-endothelial tissues (i.e. a 
thrombogenic surface) to blood flow. 
The normal resting endothelium is essentially anticoagulant. Expression of TF on the 
endothelium in response to both monocyte-derived MPs and inflammatory mediators is 
accompanied by concomitant translocation of phospholipids such as phosphatidylserine (PS) 
which may serve to enhance the binding of coagulation factors [66], while the induction of EC 
apoptosis is associated with MP generation, and downregulation of TFPI, TM and 
glycosaminoglycans such as heparan sulphate on the endothelial surface [67], with resultant 
impairment of activation of the protein C anticoagulant pathway and reduced antithrombin III 
activity, which may be partly attributed to the disrupted integrity of the endothelium. 
Activated ECs are also induced to express surface adhesion molecules which increase platelet 
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adhesion and attract monocytes and neutrophils, all of which may contribute further to 
coagulation initiation or amplification [66, 68]. At this point, the endothelial recycling process 
is overwhelmed and the innate anticoagulant mechanisms are no longer sufficient to 
counteract the procoagulant driving force of the TF. The physiological antithrombotic state is 
compromised, with the net effect that, during inflammation, the EC phenotype switches from 
thromboresistant to procoagulant [67]. 
Neutrophils in particular are found in large quantities in the plasma of cancer patients, and are 
recruited in the earliest stage of an inflammatory response [11]. Interestingly, a recent study 
found that tumour-induced neutrophils are more prone to NET formation that their normal 
counterparts in both leukaemia and solid tumour (mammary and lung carcinoma) 
experimental models, thereby promoting a cancer-associated hypercoagulable state [69]. 
These NETs have demonstrable roles in thrombosis, providing a scaffold closely intercalated 
with the fibrin matrix, enhancing thrombus formation and subsequent stabilisation, and 
facilitating the adhesion of platelets and erythrocytes [12]. Additionally they are seen to alter 
clot morphology, producing denser clots with reduced permeability and increased resistance 
to tissue plasminogen activator (tPA)-driven lysis [70], which will potentially persist for longer 
in the circulation, exacerbating the thrombotic effect. This prothrombotic fibrin clot phenotype 
has been observed in digestive tract cancers [71] and in multiple myeloma [72], while NETs 
themselves have been identified in a number of cancers, including pancreatic cancer [73], and 
pancreatic cancers cells have been shown to stimulate rapid release of NETs, promoting 
thrombus formation under venous flow conditions [74]. 
The role of NETs in cancer-associated thrombosis has recently been challenged by Nouboussie 
et al., who argue that it is the constituent products of NETs (i.e. cell-free DNA [cfDNA] and 
histones), and not intact NETs, that are able to activate coagulation [75]. However, as the 
authors admit, this observation was made only in an in vitro setting, and therefore does not 
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take into account the compounding effects of potential interactions with other relevant cells 
and effects of venous flow in vivo. 
However, neutrophils do not represent the only source of cfDNA in plasma, and other forms of 
cfDNA may contribute towards the prothrombotic state. Elevated levels of cfDNA in cancer 
patients have additionally been characterised as either tumour-derived or released from 
injured host blood or vascular tissues via apoptotic and necrotic cell death [76], and are 
thought to provide an activation surface for the contact pathway of coagulation. The effect of 
chronic inflammation in the tumour microenvironment is proposed to be similar to that 
observed in response to chronic exercise protocols, characterised by a slow, constant release 
of DNA via apoptosis or necrosis [77]. In contrast, intense exercise results in a rapid and 
transient increase of cfDNA which is thought to be attributed, at least in part, to NETosis [78]. 
It is possible that the constant cfDNA release occurring in the chronically inflamed tumour 
microenvironment may be exacerbated by the addition of an acute inflammatory stress, 
evoking further spontaneous cfDNA release in the form of NETs. In the acute exercise setting in 
healthy individuals, this is effectively counterbalanced by a concomitant increase in serum 
DNase activity [78], but the absence or inadequacy of this mechanism in cancer, accompanied 
by the persistence of neutrophils in the circulation, will likely prolong the effect. 
NETs also serve to locally concentrate neutrophil serine proteases, which are responsible for 
further promoting coagulation, again by directly counteracting endogenous anticoagulants 
[79]. Neutrophil elastase (NE), cathepsin G (CG) and proteinase-3 (PR3) have all demonstrated 
an ability to cleave and inactivate EC-bound TFPI [79, 80], while PR3 has additionally been 
found to induce expression of encrypted TF on the EC surface [80], thus shifting the balance 
even further in favour of thrombosis. Disruption of the TF:TFPI ratio is common in several 
inflammatory disease conditions, including sepsis, acute myocardial infarction and 
disseminated intravascular coagulation (DIC) [81-83]. 
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Coagulation exacerbates inflammation 
In complex with blood coagulation Factor VIIa (FVIIa), TF can also play an important role in 
intracellular non-haemostatic signalling pathways. This can lead to activation and induction of 
further inflammation, and can induce proangiogenic and immune modulating cytokines, 
chemokines and growth factors, promoting proliferation and invasiveness of cancer cells [28]. 
This effect is largely mediated by the ability of coagulation serine proteases to interact with 
PARs on the surface of monocytes and ECs [84]. Activation of multiple PARs by coagulation 
proteases is thought to contribute to inflammation in endotoxaemia and sepsis [85], and 
similarly may do the same in cancer.  
As such, high levels of TF in the form of TF-MPs can contribute to the amplification of 
inflammation via induction of PAR1 and PAR2 on ECs, through generation of thrombin and 
Factor Xa (FXa) respectively [84, 86]. This is dependent on co-localization of PAR receptors with 
their activating proteases [87], facilitated by expression of adhesion molecules and enhanced 
leukocyte trafficking by the activated ECs. Activation of PAR1 and PAR2 in turn contributes to 
the induction of acute pro-inflammatory responses within the endothelial layer, induces 
expression of proinflammatory cytokines and chemokines [85], exposing further cell adhesion 
molecules [88] and eliciting production of ROS [89], and increasing susceptibility to MP 
endocytosis.  
PAR2 is also susceptible to activation by neutrophil serine proteases. While NE, CG and PR3 
have been shown to disarm PAR2 and target it for internalization, attenuating Gq-coupled 
PAR2 calcium signalling in response to trypsin [90], NE possesses the additional ability to evoke 
PAR2-mediated Gi/G12/13-coupled activation of the p44/42 mitogen-activated protein kinase 
(MAPK) pathway and subsequent extracellular signal-related kinase (ERK) phosphorylation, 
independent of β-arrestin recruitment and receptor internalization [90]. In this respect, NE is 
able to demonstrate biased agonism, and it is possible that, under inflammatory conditions, 
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accompanied by increased neutrophil infiltration and associated high levels of neutrophil 
serine proteases, the balance of PAR2 signalling may be shifted towards NE- rather than 
trypsin-triggered MAPK signalling, targeting nuclear as opposed to non-nuclear ERK substrates 
[90]. 
The mononuclear-phagocyte system 
Monocytes, along with macrophages and dendritic cells, form an integral part of the 
mononuclear phagocyte system (formerly known as the reticuloendothelial system) and form a 
significant presence in the tumour lymphoreticular infiltrate [51]. This is a filtration system for 
the removal of insoluble cellular debris and particulate matter, classically responsible for the 
clearance of platelets [91]. It now appears that both apoptotic bodies and MPs follow a similar 
fate [54, 92], cleared from the blood by macrophages in the liver and spleen. Indeed evidence 
suggests that MPs are continuously formed and rapidly cleared from the circulation in vivo [93-
95], and it also appears that the system may be responsible for the clearance of activated 
clotting factors such as thrombin [96] and also of fibrinogen-fibrin complexes [91]. 
It follows that any TF in association with MP, and indeed any products of the coagulation 
process, under normal circumstances, are unlikely to remain in the circulation for long enough 
to accumulate to a level capable of promoting clot formation [63]. The presence of PS on the 
surface of TF-MPs, although enhancing their procoagulant potential [54], also labels them for 
phagocytic clearance [92]. However, an early study indicated that there may be transient 
reticuloendothelial dysfunction during intravascular coagulation initiated by thrombin that 
may affect clearance capacity [91]. Indeed Davizon and Lopez discuss the potential for defects 
in clearance to result in an elevated thrombotic tendency [92], exemplified by the observation 
that splenectomised patients with immune thrombocytopenia purpura (ITP) have higher levels 
of plasma MP and shortened activated partial thromboplastin time (aPTT) [97]. It is possible 
that such a defect may be the result of extraordinarily high levels of TF, resulting from the 
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combined contributions of cancer- and inflammation-related factors, which may overwhelm 
the system, resulting in a period of transient phagocytic depression, during which these 
particles persist in the blood, with continual perturbation of the vascular endothelium [98]. 
This, further aggravated by venous stasis, prevents activated coagulation factors from being 
cleared and may give the thrombosis the opportunity to develop.  
 
A homeostatic threshold? 
The model of Virchow’s triad encapsulates the multifactorial pathogenesis of VTE, where any 
single risk factor or abnormality in any one of the triad components (i.e. venous stasis, 
endothelial injury or hypercoagulability) can predispose to, but is not sufficient on its own to 
trigger thrombosis. While it is not necessary to acquire deficiency in all recognised factors, it is 
likely to be the specific interaction of several of these factors together that will cumulatively 
result in VTE. More recently, Blix and colleagues have discussed the concept of a “thrombosis 
potential”; a certain threshold for venous thrombosis reached only by a combination of 
contributory factors [47]. In accordance with this, it was noted that a high WBC count in 
isolation did not precipitate thrombosis, but did so in the context of malignancy [47], and 
Demers et al. make comment that, while neutrophil activation and NET generation are likely 
very important players in cancer-associated VTE, they are unlikely to be sufficient on their own 
[69], and may only provoke DVT in the context of an additional predisposing factor, such as 
high levels of TF-MPs. Similarly, high levels of TF-MPs by themselves, even in the context of 
malignancy, do not cross the ‘thrombosis potential’ in the majority of cancer patients. 
Interestingly the contact pathway, which is activated by NETs, is thought to participate 
significantly during thrombosis, but is considered dispensable for physiological haemostasis 
[99], emphasizing the importance of leukocytes, particularly neutrophils, perhaps in 
concentrating key proteins to stabilize the thrombus [12]. 
16 
 
The importance of the TF pathway in the initiation and propagation of VTE is undeniable, but it 
is possible that its significance may differ between cancer types. Certainly in pancreatic cancer, 
increased levels of TF-MPs do appear to be a key contributory factor, whereas their association 
with VTE in other cancer types is still a matter of debate. We propose a further putative 
mechanism for the development of VTE which, this taken into account, may be of particular 
relevance to pancreatic cancer. We suggest that, in the context of an already hypercoagulable 
state, inflammation may provide the trigger to drive the procoagulant response. The levels of 
TF expression still remain a key factor, and it is perhaps the additional effect of inflammation in 
enhancing leukocyte- and vascular TF expression that invokes optimal thrombus growth [22], 
accumulating to sufficient concentrations to overcome the physiological threshold set by the in 
vivo anticoagulant mechanisms [35], which themselves are further hampered under 
inflammatory conditions. In this sense, inflammation produces effects targeting all three 
aspects of Virchow’s triad. Venous stasis is known to promote cell-cell and MP-cell interactions 
which, in the context of increased circulating TF-MPs and increased leukocyte infiltration, 
serves to amplify procoagulant and proinflammatory effects. Inflammatory mediators also 
serve to exacerbate endothelial activation and enhance endothelial perturbation, increasing 
expression of endothelial TF via PAR1 and PAR2, inducing apoptosis, potentiating MP release 
and further shifting the haemostatic balance from anti- to pro-thrombotic. Furthermore, 
innate hypercoagulability is exacerbated by the pronounced change in the systemic balance of 
procoagulant and anticoagulant factors elicited by inflammatory mediators. In particular, the 
induction of further TF expression may contribute to levels which are sufficiently high enough 
to, in the absence of effective counteracting effects, overwhelm natural homeostatic 
mechanisms. For example, in the setting of inflammatory conditions, such as sepsis and 
endotoxaemia, which can induce a hypercoagulable state, acute DIC only results when 
regulatory mechanisms are overwhelmed [100]. In a similar way, the high levels of TF observed 
when cancer and inflammation combine, may temporarily overwhelm the natural clearance 
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system, leading to accumulation of TF-MPs and coagulation products, serving to prolong their 
prothrombotic effect in vivo [35]. 
This hypothesis is illustrated in Figure 1. An innate haemostatic homeostasis is maintained 
under normal physiological conditions (Fig. 1.a.), where the presence of small amounts of TF in 
the form of TF-MPs are easily counteracted by swift activation of anticoagulant mechanisms 
and rapid clearance from the blood system via the endothelium and the mononuclear 
phagocyte system. Similarly, in a cancer setting, but in the absence of inflammation (or any 
other instigating factor for endothelial disruption) (Fig. 1.b.), the levels of TF-MPs are likely 
raised, but are still controlled by innate mechanisms and are not sufficient to exceed the 
thrombotic threshold and the homeostasis is maintained. In contrast, the addition of 
inflammation (Fig 1.c.) provides an additional TF stimulus via increased leukocyte infiltration 
and increased endothelial expression via activation of PAR receptors, and the induction of 
endothelial apoptosis due to accumulating levels of TF can result in exposure of procoagulant 
subendothelial layers (Fig. 1.c.ii.). The mechanisms maintaining TF-MP homeostasis may be 
overwhelmed (Fig. 1.c.i.); anticoagulant mechanisms no longer compensate for the increase 
and a transient depression of clearance processes (by an as yet undetermined mechanism) 
allow the threshold to be reached and thrombosis formation to occur. 
The interplay of all these processes may explain why the hospital seems to operate as such an 
‘incubator’ of VTE; either through necessity (infection, obstruction, perforation, fracture) or 
design (planned intervention, surgery, implantation of device, chemotherapy), the precarious 
‘chronic’ yet ‘contained through homeostatic mechanisms’ cancer coagulopathy is tipped to 
produce a clinically overt thrombotic event. Although this event may phenotypically come 
together as a thrombosis, very similarly to the way in which the coagulation cascade comes 
together to form thrombin, the actual constituent thrombo-anomalies may be very different 
from cancer to cancer and case to case. 
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